E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Anterior ST-Elevation Myocardial Infarction |
Infarto miocardico in sede anteriore con sopraslivellamento del tratto ST |
|
E.1.1.1 | Medical condition in easily understood language |
Myocardial Infarct (heart attack) |
Infarto del miocardio (attacco cardiaco) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10007541 |
E.1.2 | Term | Cardiac disorders |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the effect of FDY-5301 on cardiovascular mortality and heart failure events in subjects with an anterior STEMI undergoing pPCI. |
Valutare l’effetto di FDY-5301 sulla mortalità cardiovascolare e sugli eventi di insufficienza cardiaca in soggetti con STEMI anteriore sottoposti a pPCI. |
|
E.2.2 | Secondary objectives of the trial |
To assess the effect of FDY-5301 on other clinical outcomes such as all-cause mortality and cardiovascular outcomes in subjects with an anterior STEMI undergoing pPCI |
Valutare l’effetto di FDY-5301 su altri esiti clinici come mortalità per qualsiasi causa ed esiti cardiovascolari in soggetti con STEMI anteriore sottoposti a pPCI. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Age >= 18 years 2. Anterior STEMI, based on: Symptoms of myocardial ischemia (such as chest pain, shortness of breath, jaw pain, arm pain, diaphoresis, or any anginal equivalent) and ECG criteria: • men > 40 years: >= 2 mm of ST elevation in V2 and V3 • men <= 40 years: >= 2.5 mm of ST elevation in V2 and V3 • women: >= 1.5 mm of ST elevation in V2 and V3 3. Planned primary PCI to occur <= 6 hours of onset of first symptoms of myocardial ischemia 4. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved consent obtained for study participation |
1. Età >=18 anni 2. STEMI anteriore, in base a: Sintomi di ischemia miocardica (quali dolore toracico, respiro affannoso, dolore mandibolare, dolore al braccio, diaforesi o qualsiasi sintomo anginoso equivalente) e Criteri relativi all’elettrocardiogramma (ECG): • Uomini di età >40 anni: >=2 mm di sopraslivellamento del tratto ST in V2 e V3; • Uomini di età <=40 anni: >=2,5 mm di sopraslivellamento del tratto ST in V2 e V3; • Donne: >=1,5 mm di sopraslivellamento del tratto ST in V2 e V3. 3. PCI primario la cui esecuzione è programmata =<6 ore dall’insorgenza dei primi sintomi di ischemia miocardica 4. Acquisizione del consenso alla partecipazione allo studio approvato dal Comitato etico indipendente (CEI) |
|
E.4 | Principal exclusion criteria |
1. Life expectancy of less than 1 year due to non-cardiac pathology 2. Known thyroid disease or thyroid disorder, including subjects on thyroid hormone replacement therapy at the time of randomization 3. Known allergy to iodine 4. Renal disease requiring dialysis 5. Women who are pregnant or breastfeeding. Women of reproductive potential must have a negative pregnancy test prior to randomization 6. Body weight >140 kg 7. Use of thrombolytic therapy as treatment for the index STEMI event 8. Use of investigational drugs or devices 30 days prior to randomization 9. Any clinically significant abnormality identified prior to randomization that in the judgment of the Investigator or Sponsor would preclude safe completion of the study, or confound the anticipated benefit of FDY-5301 |
1. Aspettativa di vita inferiore a 1 anno a causa di una patologia non cardiaca
2. Malattia o disturbo tiroidea/o nota/o, inclusi i soggetti sottoposti a una terapia sostitutiva con ormoni tiroidei al momento della randomizzazione
3. Allergia nota allo iodio
4. Malattia renale che richiede il ricorso alla dialisi
5. Soggetti di sesso femminile in gravidanza o che stanno allattando al seno. Le donne in età fertile devono risultare negative al test di gravidanza prima della randomizzazione
6. Peso corporeo >140 kg
7. Uso di una terapia trombolitica come trattamento per l’evento STEMI indice
8. Uso di farmaci o dispositivi sperimentali nei 30 giorni che precedono la randomizzazione
9. Qualsiasi anomalia clinicamente significativa identificata prima della randomizzazione che, a giudizio dello sperimentatore o dello Sponsor, precluderebbe il completamento sicuro dello studio o confonderebbe il beneficio previsto di FDY-5301 |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The proportion of subjects who experience either cardiovascular mortality (defined as deaths which are sudden and due to presumed arrhythmia, or deaths due to presumed or confirmed thromboembolic CVA, presumed or confirmed pulmonary embolism, cardiac rupture, heart failure, recurrent myocardial infarction [e.g., remote or stent thrombosis], and deaths due to procedural efforts to treat these defined cardiac events), or a heart failure event through Month 12 |
Percentuale di soggetti che manifestano mortalità cardiovascolare (definita come decesso improvviso dovuto a presunta aritmia o decesso dovuto ad accidente tromboembolico cerebrovascolare presunto o confermato, embolia polmonare presunta o confermata, rottura cardiaca, insufficienza cardiaca, infarto miocardico ricorrente [ad es. trombosi remota o da stent] e decesso dovuto a tentativi procedurali di trattare questi eventi cardiaci definiti) o un evento di insufficienza cardiaca fino al Mese 12. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
through month 12 |
fino al mese 12 |
|
E.5.2 | Secondary end point(s) |
•The proportion of subjects who experience either all-cause mortality or a heart failure event through Month 12 •The total number of cardiovascular events defined as cardiovascular mortality and heart failure events through Month 12 •The proportion of subjects who experience specified non-fatal cardiovascular events of thromboembolic cerebral vascular accident (CVA), ventricular aneurysm/hemorrhage, recurrent myocardial infarction (e.g., remote or stent thrombosis), or persistent arrhythmia through Month 12 •Serum troponin T at Day 3 |
• Percentuale di soggetti che manifestano mortalità per qualsiasi causa o un evento di insufficienza cardiaca fino al Mese 12 • Numero totale di eventi cardiovascolari definiti come mortalità cardiovascolare ed eventi di insufficienza cardiaca fino al Mese 12 • Percentuale di soggetti che manifestano eventi cardiovascolari non fatali specificati di accidente cerebrovascolare (ACV) tromboembolico, |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
see E.5.2 for evaluation timing |
vedere la sezione E.5.2 per il tempo di rilevazione |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 67 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
Israel |
United States |
Poland |
Netherlands |
Spain |
Czechia |
Germany |
Italy |
Hungary |
Portugal |
Slovakia |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |